GLP-1s for men: separating science from hype
Semaglutide and tirzepatide are the most consequential weight-loss drugs of the decade. Here's what the evidence actually says — and what it doesn't.
GLP-1 receptor agonists — semaglutide, tirzepatide, and the rest — have reshaped men's health practice over the last two years. The clinical benefits are real, but so is the hype. A short field guide.
What the evidence supports
- ~15-25% body weight reduction over a year on tirzepatide; ~12-18% on semaglutide. Both substantially more effective than older oral agents.
- Cardiovascular benefit in patients with overweight + established CV disease (SELECT trial).
- Improvements in fatty liver, sleep apnea severity, glycemic control.
What the evidence does not yet support
- GLP-1s as a universal anti-aging or longevity drug.
- Maintaining weight loss after discontinuation. Regain is the default unless lifestyle changes hold.
- Use in patients with normal BMI for cosmetic recomposition.
Side effects + monitoring
Nausea is universal and dose-dependent. Constipation is common. Gallbladder events show up over time. Muscle-mass loss is a real concern in men using GLP-1s at high doses without protein + resistance training.
Anyone starting a GLP-1 should be on a structured titration, have baseline labs, and ideally see DEXA or body-composition data at start and 6 months. Cash-pay mills that ship the medication without follow-up are the wrong way to do this.
Tagged
- GLP-1
- Evidence
- Off-label